STVN — Stevanato Group S.p.A.

Summary of Stevanato Group (STVN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: €346.5 million, up 7% at constant currency and 5% reported.
• Full Year 2025 Revenue: Increased by 9% at constant currency and 7% reported compared to 2024.
• Gross Profit Margin: Improved by 120 basis points to 30.9% in Q4 2025.
• Operating Profit Margin: 20.2% for Q4 2025.
• Net Profit: €47.6 million for Q4; adjusted net profit was €49.8 million.
• Adjusted EBITDA: Increased 7% to €97.7 million with a margin of 28.2%.
• Cash Flow: Positive free cash flow of €18.4 million for the full year 2025.

2. Strategic Updates and Business Highlights

• Biopharmaceutical and Diagnostic Solutions (BDS): Strong performance with revenue growth of 13% in Q4, driven by high-value solutions, particularly the Nexa syringe, which saw a 31% increase in revenue.
• Engineering Segment: Experienced a 23% revenue decline in Q4 due to lower order intake but made operational improvements.
• Investment in Capacity: Continued investment in facilities in Fishers, Indiana, and Latina, Italy, to expand production capacity for high-value syringes and cartridges.
• Customer Engagement: Increased participation in biologics, with 41% of BDS revenues coming from biologics, up from 34% in 2024.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between €1.260 billion and €1.290 billion; adjusted EBITDA projected at €331.8 million to €346.9 million.
• GLP-1 Revenue Contribution: Anticipated to grow in the mid-teens percentage range in 2026, contributing 47%-48% of total revenue.
• Engineering Segment Outlook: Expected to decline by mid-single to low double digits in 2026 due to lower order intake.

4. Bad News, Challenges, or Points of Concern

• Engineering Segment Decline: The engineering segment faced a significant revenue drop and is experiencing slow order intake, which may hinder recovery.
• Foreign Currency Headwinds: Expected to impact revenue by approximately €18 million in 2026.
• Operational Challenges: The sales cycle for new orders in the engineering segment is longer than anticipated, affecting order conversion rates.
• Market Dynamics: Increased competition and evolving market conditions in the biopharmaceutical sector may pose risks.

5. Notable Q&A Insights

• GLP-1 Growth Expectations: Management expects mid-teens growth for GLP-1s in 2026, citing robust demand but acknowledging a normalization after a surge in 2025.
• Engineering Segment Strategy: Focused on improving operational execution and increasing order intake, with a healthy pipeline but slower conversion to orders.
• High-Value Solutions: Continued emphasis on high-value products, with a notable increase in customers ordering premium ranges.
• Market Positioning: Stevanato aims to be a leading partner in the biologics market, focusing on high-value solutions and adapting to evolving customer needs.

Overall, Stevanato Group reported solid financial results for 2025, with strong growth in high-value solutions, but faces challenges in its engineering segment and external market pressures. The company remains optimistic about future growth driven by GLP-1s and other biologics.